Vaxcyte, Inc. $PCVX Shares Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. grew its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 64.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,184 shares of the company’s stock after purchasing an additional 9,074 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Vaxcyte were worth $835,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of PCVX. CWM LLC lifted its stake in shares of Vaxcyte by 197.3% during the second quarter. CWM LLC now owns 1,680 shares of the company’s stock valued at $55,000 after buying an additional 1,115 shares during the period. Blue Trust Inc. raised its holdings in Vaxcyte by 176.7% in the 2nd quarter. Blue Trust Inc. now owns 2,161 shares of the company’s stock valued at $70,000 after acquiring an additional 1,380 shares during the last quarter. Virtus Investment Advisers LLC lifted its stake in shares of Vaxcyte by 45.8% during the 2nd quarter. Virtus Investment Advisers LLC now owns 2,729 shares of the company’s stock worth $89,000 after purchasing an additional 857 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of Vaxcyte by 96.3% during the third quarter. Nisa Investment Advisors LLC now owns 3,254 shares of the company’s stock worth $117,000 after purchasing an additional 1,596 shares during the last quarter. Finally, J.Safra Asset Management Corp boosted its holdings in shares of Vaxcyte by 18.5% during the second quarter. J.Safra Asset Management Corp now owns 3,746 shares of the company’s stock worth $122,000 after purchasing an additional 585 shares during the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PCVX has been the subject of several analyst reports. BTIG Research reiterated a “buy” rating and issued a $85.00 target price on shares of Vaxcyte in a research note on Monday, November 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday, January 9th. Guggenheim reiterated a “buy” rating and set a $116.00 price objective on shares of Vaxcyte in a report on Monday. Needham & Company LLC raised their target price on shares of Vaxcyte from $90.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Finally, Leerink Partners set a $77.00 price target on shares of Vaxcyte and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $93.83.

Vaxcyte Price Performance

NASDAQ PCVX opened at $55.28 on Thursday. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $91.77. The firm has a market capitalization of $7.24 billion, a P/E ratio of -11.42 and a beta of 1.33. The business’s 50-day simple moving average is $47.83 and its 200-day simple moving average is $41.24.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, November 4th. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.29). During the same period in the previous year, the business earned ($0.83) EPS. On average, equities research analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Insider Buying and Selling at Vaxcyte

In related news, SVP Elvia Cowan sold 11,623 shares of the stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $47.92, for a total value of $556,974.16. Following the completion of the sale, the senior vice president directly owned 14,534 shares in the company, valued at approximately $696,469.28. This represents a 44.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Harpreet S. Dhaliwal sold 9,743 shares of the firm’s stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $46.69, for a total value of $454,900.67. Following the completion of the transaction, the insider directly owned 23,928 shares in the company, valued at $1,117,198.32. This trade represents a 28.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.10% of the stock is owned by corporate insiders.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.